Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone [8] (multiple letters)

American Journal of Medicine

Volumn 111, Issue 7, 2001, Pages 587-

  Berry, Colin ^a   McMurray, John ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; POTASSIUM; SPIRONOLACTONE;

CLINICAL TRIAL; DEATH; DEHYDRATION; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; LABORATORY TEST; LETTER; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; VOMITING;

EID: 0035159709     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(01)00927-5     Document Type: Letter

References (5)

1. H. Schepkens R. Vanholder J.M. Billiouw N. Lamiere Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone an analysis of 25 cases Am J Med 110 2001 438 441
2. C. Berry J.J.V. McMurray Serious adverse events experienced by patients with chronic heart failure taking spironolactone Heart 85 2001 e8 e9
3. B. Pitt F. Zannad W.J. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717
4. J. McMurray D.M. Matthews Consequences of fluid loss in patients treated with ACE inhibitors Postgrad Med J 63 1987 385 387
5. B. Pitt L.A. Pierard A. Bilge Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]) Am J Cardiol 78 1996 902 907